Skip to content
value.today

Gradalis, Inc.

🇺🇸 Dallas, Texas, USAPharmaceuticalsFounded 2014

Formerly Murex Pharmaceuticals, Inc.

Total raised
$57 M
2 rounds on record
Latest round
$13 M
Jun 2025
First round on record
Mar 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Gradalis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$13 MNo. 2$10 to $50 million

Gradalis, Inc.: Raise no. 2, Jun 2025

Investors in this round

24 investors had bought by the notice of Jun 12, 2025: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $30 M offered; $17 M still to sell
Smallest investment taken
$250,000
What was sold
debt, options or other rights to buy securities, other: Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Shanahan · Executive Officer, Director
  • John P. Nemunaitis · Executive Officer, Director
  • Mark C. Early · Executive Officer
  • Harry R. Jacobson · Director
  • Joe C. Cunningham · Director
  • Joseph F. Berry · Director
  • Robert P. Landin · Director
  • Scott C. Seaman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Early, General Counsel. Source: SEC Form D, newest notice filed Jun 12, 2025. Read the notice at the SEC.

debt, optionsSEC
Mar 2018$44 MNo. 1$10 to $50 million

Gradalis, Inc.: Raise no. 1, Mar 2018

Investors in this round

36 investors had bought by the notice of Apr 2, 2018: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$44 M of $55 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Shanahan · Executive Officer, Director
  • Ernest Bognar · Executive Officer
  • Gladice Wallraven · Executive Officer
  • John Nemunaitis, M.D. · Executive Officer, Director
  • Renee Larson · Executive Officer
  • Harry Jacobson, M.D. · Director
  • Joe Cunningham, M.D. · Director
  • Robert Landin · Director
  • Scott Seaman · Director
  • Thomas Lyles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Shanahan, Ceo. Source: SEC Form D, newest notice filed Apr 2, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Gradalis, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).

    SEC Form D · Jun 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2025

That is all the official record says: Gradalis, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Gradalis, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gradalis, Inc.
NameRoleNamed in
David M. ShanahanExecutive officerJun 2025
John P. NemunaitisExecutive officerJun 2025
Mark C. EarlyExecutive officerJun 2025
David ShanahanExecutive officerApr 2018
Ernest BognarExecutive officerApr 2018
Gladice WallravenExecutive officerApr 2018
John Nemunaitis, M.D.Executive officerApr 2018
Renee LarsonExecutive officerApr 2018
David M. ShanahanDirectorJun 2025
Harry R. JacobsonDirectorJun 2025
Joe C. CunninghamDirectorJun 2025
John P. NemunaitisDirectorJun 2025
Joseph F. BerryDirectorJun 2025
Robert P. LandinDirectorJun 2025
Scott C. SeamanDirectorJun 2025
David ShanahanDirectorApr 2018
Harry Jacobson, M.D.DirectorApr 2018
Joe Cunningham, M.D.DirectorApr 2018
John Nemunaitis, M.D.DirectorApr 2018
Robert LandinDirectorApr 2018
Scott SeamanDirectorApr 2018
Thomas LylesDirectorApr 2018